Lower Respiratory Tract Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Lower Respiratory Tract Therapeutics Market is segmented by Disease Type (Asthma, Chronic obstructive pulmonary disease, Pneumonia, Tuberculosis, Bronchitis, Others), By Drug Class (Antibiotics, Non-steroidal anti-inflammatory drug, Cough Suppressant, Nasal decongestant, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.

Lower Respiratory Tract Therapeutics Market Size

The Global Lower Respiratory Tract Therapeutics Market size reached USD 32,312.9 million in 2022 and is projected to witness lucrative growth by reaching up to USD 56,251.7 million by 2031. The global lower respiratory tract therapeutics market is expected to exhibit a CAGR of 7.3% during the forecast period (2024-2031). The key market trend is the widespread increase in industry smoke-related and smoking respiratory diseases.

For instance, in May 2023, The Washington State Department of Labor & Industries proposed permanent wildfire smoke rules to protect people who work outdoor jobs from the risk of reduced lung function, asthma, heart failure, and early death. The rules are designed to protect workers from the tiny particles carried by the smoke.

Lower respiratory tract therapeutics is the branch of medicine that focuses on the diagnosis, treatment, and management of diseases and disorders affecting the lower respiratory system. Treatment plans are tailored to the specific condition and severity of symptoms experienced by the individual patient. Lower respiratory tract therapeutics involve medication, respiratory therapies, and lifestyle modifications. 

The lower respiratory tract therapeutics market is driven by factors such as the increasing prevalence of lower respiratory tract diseases, the rising aging population, increasing awareness and diagnosis, government initiatives and healthcare policies, environmental factors (such as air pollution, climate change, and allergens), and technological advancements.

For instance, in March 2023, London’s ultra-low emission zones (ULEZ) project, which seeks to prevent respiratory tract issues caused by unhealthy air uses mobile air quality monitoring technology to monitor air quality and it aims to reduce one million hospital admissions by 2050.

Lower Respiratory Tract Therapeutics Market Summary

To Get a Free Sample Click here

Lower Respiratory Tract Therapeutics Market Dynamics

Increasing Prevalence Of Lower Respiratory Tract Diseases

The increasing prevalence of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia is a significant driver for the lower respiratory tract therapeutics market during the forecast period. Factors such as pollution, smoking, occupational hazards, and lifestyle changes contribute to the growing burden of respiratory diseases globally.

Smoking is a leading cause of lower respiratory tract diseases, including chronic obstructive pulmonary disease (COPD), lung cancer, and respiratory infections. The continued use of tobacco products, both in traditional and emerging forms, contributes to the development and progression of these conditions.

Higher Risk Of Adverse Effects

The adverse effects associated with the treatment of lower respiratory tract diseases are a major factor hampering the market growth during the forecast period. The safety and tolerability profiles of lower respiratory tract therapeutics are crucial considerations. Adverse effects associated with medications, such as systemic corticosteroids or bronchodilators, can limit their use and affect patient compliance. 

Some lower respiratory tract therapeutics, especially those taken orally or intravenously, can have systemic effects beyond the respiratory system. These effects can include gastrointestinal disturbances, cardiovascular effects (e.g., increased heart rate, hypertension), immunosuppression, electrolyte imbalances, and so on.

Lower Respiratory Tract Therapeutics Market Segment Analysis

The global lower respiratory tract therapeutics market is segmented based on disease type, drug class, route of administration, distribution channel, end-user, and region.

Based on Disease Type, The Asthma Therapeutics Segment Is Expected To Dominate The Market Share 

Based on the disease type, the asthma therapeutics segment is expected to dominate the market share during the forecast period. The market for asthma therapeutics holds the 45.3% of the market share in 2022. Asthma is a chronic inflammatory disease of the airways characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. It affects a large population worldwide, including both children and adults.

There is a growing emphasis on personalized medicine approaches in asthma management. Advancements in biomarker testing, such as fractional exhaled nitric oxide (FeNO) and specific IgE levels, help identify patients who are likely to respond to specific therapies. This personalized approach enables more targeted treatment selection, enhancing the effectiveness of asthma therapeutics.

Source: DataM Intelligence Analysis (2023)

Lower Respiratory Tract Therapeutics Market Geographical Share

North America Holds The Largest Market Share Due To The High Disease Burden And Technological Advancements

North America holds the largest market share during the forecast period due to the high disease burden and technological advancements. The region held 38.1% market share for the lower respiratory tract therapeutics market in 2022. North America has a relatively high prevalence of respiratory diseases such as asthma and COPD. 

Factors such as environmental pollution, smoking rates, and an aging population contribute to the significant disease burden in the region. The large patient population requiring respiratory therapeutics drives the market growth. The technological advancements in treatment options are also a significant factor driving the market share in the region. 

Source: DataM Intelligence Analysis (2023)

Lower Respiratory Tract Therapeutics Companies

The major global players include F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi S.A, Pfizer Inc., GSK plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd., and Merck & Co., Inc.

COVID-19 Impact on Lower Respiratory Tract Therapeutics Market

The COVID-19 pandemic has had a significant impact on the lower respiratory tract therapeutics market. With the emergence of the COVID-19 virus, there has been a substantial shift in focus towards developing therapeutics for the treatment of COVID-19 respiratory infections. Pharmaceutical companies and researchers have directed their efforts towards developing antiviral drugs, monoclonal antibodies, and other therapies specifically targeting COVID-19. 

This diversion of resources and attention towards COVID-19 treatments has had implications for the development and marketing of other lower respiratory tract therapeutics.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war significantly impacted the lower respiratory tract therapeutics market growth. The ongoing conflict between Russia and Ukraine has broader geopolitical and socio-economic implications. While it may indirectly impact healthcare sectors, including the lower respiratory tract therapeutics market. 

The war can put a strain on the healthcare infrastructure, leading to challenges in providing adequate healthcare services, including respiratory care. Damage to hospitals, clinics, and healthcare facilities can further exacerbate the strain on the healthcare system.

Key Developments

• In May 2023, Pfizer Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the available data support the efficacy and safety of its unadjuvanted bivalent respiratory syncytial virus (RSV) prefusion F vaccine candidate RSVpreF or PF-06928316. The Committee voted 14 to 0 on effectiveness and 10 to 4 on safety. The vaccine candidate is currently under FDA review for the prevention of medically attended lower respiratory tract disease (MA-LRTD) and severe MA-LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals.
• In May 2023, The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) in 29 low- and middle-income countries over the next three years. This collaboration advances each organization’s focus on patient access by combining Max’s expertise and infrastructure with a donated product from BeiGene, and a grant from the BeiGene Foundation.

Why Purchase the Report?

• To visualize the global lower respiratory tract therapeutics market segmentation based on disease type, drug class, route of administration, distribution channel, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of lower respiratory tract therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global lower respiratory tract therapeutics market report would provide approximately 54 tables, 46 figures, and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies